Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vbi Vaccines Inc's Business Segments
Vbi Vaccines Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
1
Vbi Vaccines Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- Europe16.6%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 0 | 16.6% |
Revenue by Product & Service Category - FY
- Product80.6%
- Service19.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1 | 80.6% |
| Service | $ 0 | 19.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Vbi Vaccines Inc
VBI Vaccines Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It is focused on the development of next-generation vaccines against infectious diseases and immuno-oncology. The company was founded in 2015 and has quickly gained recognition for its innovative approach to vaccine development.
VBI Vaccines Inc leverages its proprietary enveloped virus-like particle (eVLP) platform to create novel vaccines that target a wide range of diseases. The eVLP platform allows for the production of a vaccine that closely mimics the natural virus, thereby eliciting a stronger immune response compared to traditional vaccines.
The company's pipeline consists of several vaccine candidates targeting infectious diseases such as hepatitis B, cytomegalovirus (CMV), and the Zika virus. Additionally, VBI Vaccines Inc is also focused on developing immuno-oncology therapies that stimulate the immune system to fight cancer cells.
One of the company's lead vaccine candidates is Sci-B-Vac, a trivalent hepatitis B vaccine designed to provide improved protection compared to existing vaccines. Sci-B-Vac has already been approved for use in Israel, and VBI Vaccines Inc is seeking regulatory approval in other countries as well.
VBI Vaccines Inc is also actively exploring the use of its eVLP platform for the development of vaccines against CMV, a common viral infection that can cause serious complications in immunocompromised individuals. The company's CMV vaccine candidate, VBI-2601, has shown promising results in preclinical studies and is currently being evaluated in clinical trials.
Another notable vaccine candidate in the company's pipeline is VBI-1901, which is being developed for the treatment of glioblastoma, a type of brain cancer. VBI-1901 incorporates tumor-specific antigens to stimulate an immune response against cancer cells and has shown encouraging results in early-stage clinical trials.
In addition to its vaccine development programs, VBI Vaccines Inc also collaborates with other organizations and institutions to advance its research and development efforts. The company has partnerships with the National Research Council of Canada and the National Institute of Allergy and Infectious Diseases, among others.
Overall, VBI Vaccines Inc is at the forefront of developing innovative vaccines against infectious diseases and immuno-oncology therapies. The company's use of the eVLP platform and its focus on addressing unmet medical needs make it a promising player in the biopharmaceutical industry.
VBI Vaccines Inc leverages its proprietary enveloped virus-like particle (eVLP) platform to create novel vaccines that target a wide range of diseases. The eVLP platform allows for the production of a vaccine that closely mimics the natural virus, thereby eliciting a stronger immune response compared to traditional vaccines.
The company's pipeline consists of several vaccine candidates targeting infectious diseases such as hepatitis B, cytomegalovirus (CMV), and the Zika virus. Additionally, VBI Vaccines Inc is also focused on developing immuno-oncology therapies that stimulate the immune system to fight cancer cells.
One of the company's lead vaccine candidates is Sci-B-Vac, a trivalent hepatitis B vaccine designed to provide improved protection compared to existing vaccines. Sci-B-Vac has already been approved for use in Israel, and VBI Vaccines Inc is seeking regulatory approval in other countries as well.
VBI Vaccines Inc is also actively exploring the use of its eVLP platform for the development of vaccines against CMV, a common viral infection that can cause serious complications in immunocompromised individuals. The company's CMV vaccine candidate, VBI-2601, has shown promising results in preclinical studies and is currently being evaluated in clinical trials.
Another notable vaccine candidate in the company's pipeline is VBI-1901, which is being developed for the treatment of glioblastoma, a type of brain cancer. VBI-1901 incorporates tumor-specific antigens to stimulate an immune response against cancer cells and has shown encouraging results in early-stage clinical trials.
In addition to its vaccine development programs, VBI Vaccines Inc also collaborates with other organizations and institutions to advance its research and development efforts. The company has partnerships with the National Research Council of Canada and the National Institute of Allergy and Infectious Diseases, among others.
Overall, VBI Vaccines Inc is at the forefront of developing innovative vaccines against infectious diseases and immuno-oncology therapies. The company's use of the eVLP platform and its focus on addressing unmet medical needs make it a promising player in the biopharmaceutical industry.
Vbi Vaccines Inc. is a biotechnology company focused on developing innovative vaccine candidates and immunotherapeutic products. The company primarily concentrates on the prevention of infectious diseases and the treatment of cancer. Here’s an extensive overview of the segments, products, and services offered by Vbi Vaccines Inc.:
Segments
1. Infectious Diseases:
- Vbi Vaccines develops vaccines aimed at preventing various infectious diseases, including viral infections that pose significant public health challenges. This segment includes vaccine candidates targeting diseases like hepatitis B and other viral pathogens.
2. Oncology:
- The oncology segment focuses on developing therapeutic vaccines that stimulate the immune system to fight cancer. These candidates are designed to provoke a tumor-specific immune response to eliminate cancer cells, potentially improving outcomes in cancer patients.
3. Platform Technologies:
- Vbi Vaccines utilizes proprietary technologies to create its vaccine candidates, including its core platform technologies centered around virus-like particles (VLPs) and enveloped virus-like particles (eVLPs). These platforms enhance the immune systems response and provide a versatile basis for multiple vaccine formulations.
Products
1. VBV-001 (Hepatitis B Vaccine):
- A novel vaccine candidate aimed at preventing hepatitis B infection and aiming for a functional cure for chronic hepatitis B patients. VBV-001 is designed to elicit strong immune responses to provide both safety and efficacy.
2. VBI-1901 (Glioblastoma Vaccine):
- This investigational vaccine is designed for the treatment of glioblastoma, a highly aggressive brain tumor. VBI-1901 targets glioblastoma-associated antigens to stimulate a specific immune response, potentially improving survival rates in patients.
3. VBI-1501 (Cervical Cancer Vaccine):
- A program focused on developing a vaccine for cervical cancer that targets the human papillomavirus (HPV) causing the disease. The vaccine aims to improve immune recognition of HPV-infected cells and reduce the incidence of cervical cancer.
4. Vaccine Candidates for Viral Infections:
- In addition to hepatitis B, Vbi Vaccines is exploring vaccines for other viral infections, utilizing its innovative platform technologies to potentially address a range of viral pathogens.
Services
1. Research and Development:
- Vbi Vaccines invests significantly in R&D activities to advance its vaccine candidates from preclinical stages through clinical trials. This includes laboratory research, preclinical studies, and various phases of clinical trials.
2. Partnerships and Collaborations:
- The company often engages in strategic partnerships with other biotech firms, academic institutions, and governmental organizations to further their research and development efforts, share knowledge, and improve vaccine efficacy.
3. Regulatory Support and Consulting:
- Vbi Vaccines supports the regulatory processes required to bring its vaccine candidates to market, ensuring compliance with the required industry standards and regulations.
4. Educational and Outreach Programs:
- Vbi Vaccines may engage in initiatives aimed at educating healthcare providers and the public about the importance of vaccination and the specific vaccines under development.
In summary, Vbi Vaccines Inc. offers a variety of products primarily aimed at infectious diseases and cancer treatment through innovative vaccine candidates, supported by robust research and development efforts and strategic collaborations. The company continues to explore the potential of its platform technologies to broaden its vaccine portfolio and address significant health challenges.
Segments
1. Infectious Diseases:
- Vbi Vaccines develops vaccines aimed at preventing various infectious diseases, including viral infections that pose significant public health challenges. This segment includes vaccine candidates targeting diseases like hepatitis B and other viral pathogens.
2. Oncology:
- The oncology segment focuses on developing therapeutic vaccines that stimulate the immune system to fight cancer. These candidates are designed to provoke a tumor-specific immune response to eliminate cancer cells, potentially improving outcomes in cancer patients.
3. Platform Technologies:
- Vbi Vaccines utilizes proprietary technologies to create its vaccine candidates, including its core platform technologies centered around virus-like particles (VLPs) and enveloped virus-like particles (eVLPs). These platforms enhance the immune systems response and provide a versatile basis for multiple vaccine formulations.
Products
1. VBV-001 (Hepatitis B Vaccine):
- A novel vaccine candidate aimed at preventing hepatitis B infection and aiming for a functional cure for chronic hepatitis B patients. VBV-001 is designed to elicit strong immune responses to provide both safety and efficacy.
2. VBI-1901 (Glioblastoma Vaccine):
- This investigational vaccine is designed for the treatment of glioblastoma, a highly aggressive brain tumor. VBI-1901 targets glioblastoma-associated antigens to stimulate a specific immune response, potentially improving survival rates in patients.
3. VBI-1501 (Cervical Cancer Vaccine):
- A program focused on developing a vaccine for cervical cancer that targets the human papillomavirus (HPV) causing the disease. The vaccine aims to improve immune recognition of HPV-infected cells and reduce the incidence of cervical cancer.
4. Vaccine Candidates for Viral Infections:
- In addition to hepatitis B, Vbi Vaccines is exploring vaccines for other viral infections, utilizing its innovative platform technologies to potentially address a range of viral pathogens.
Services
1. Research and Development:
- Vbi Vaccines invests significantly in R&D activities to advance its vaccine candidates from preclinical stages through clinical trials. This includes laboratory research, preclinical studies, and various phases of clinical trials.
2. Partnerships and Collaborations:
- The company often engages in strategic partnerships with other biotech firms, academic institutions, and governmental organizations to further their research and development efforts, share knowledge, and improve vaccine efficacy.
3. Regulatory Support and Consulting:
- Vbi Vaccines supports the regulatory processes required to bring its vaccine candidates to market, ensuring compliance with the required industry standards and regulations.
4. Educational and Outreach Programs:
- Vbi Vaccines may engage in initiatives aimed at educating healthcare providers and the public about the importance of vaccination and the specific vaccines under development.
In summary, Vbi Vaccines Inc. offers a variety of products primarily aimed at infectious diseases and cancer treatment through innovative vaccine candidates, supported by robust research and development efforts and strategic collaborations. The company continues to explore the potential of its platform technologies to broaden its vaccine portfolio and address significant health challenges.